Loading...
Header Logo
Keywords
Last Name
Institution

Boris Shor

TitleAssistant Professor
InstitutionUniversity of Houston
DepartmentPolitical Science
Address4800 Calhoun Rd
Houston TX 77004
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 09; 18(5):1101-16. PMID: 27198897.
      View in: PubMed
    2. Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, Wang F, Melamud E, Sapra P. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Clin Cancer Res. 2016 Jan 15; 22(2):383-94. PMID: 26319086.
      View in: PubMed
    3. Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015 Oct; 67(2 Pt A):107-16. PMID: 25304309.
      View in: PubMed
    4. He H, Ratnayake AS, Janso JE, He M, Yang HY, Loganzo F, Shor B, O'Donnell CJ, Koehn FE. Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues. J Nat Prod. 2014 Aug 22; 77(8):1864-70. PMID: 25098528.
      View in: PubMed
    5. Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013 Jun; 138(3):452-69. PMID: 23507041.
      View in: PubMed
    6. Shor B, Wu J, Shakey Q, Toral-Barza L, Shi C, Follettie M, Yu K. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem. 2010 May 14; 285(20):15380-92. PMID: 20233713; PMCID: PMC2865278.
      View in: PubMed, PubMed Central
    7. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010 Jan 15; 70(2):621-31. PMID: 20068177.
      View in: PubMed
    8. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009 Dec; 8(23):3831-7. PMID: 19901542.
      View in: PubMed
    9. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 01; 69(15):6232-40. PMID: 19584280.
      View in: PubMed
    10. Shor B, Cavender D, Harris C. A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice. BMC Immunol. 2009 May 20; 10:28. PMID: 19457267; PMCID: PMC2698930.
      View in: PubMed, PubMed Central
    11. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 2008 Apr 15; 68(8):2934-43. PMID: 18413763.
      View in: PubMed
    12. Zhang WG, Shor B, Yu K. Identification and characterization of a constitutively T-loop phosphorylated and active recombinant S6K1: expression, purification, and enzymatic studies in a high capacity non-radioactive TR-FRET Lance assay. Protein Expr Purif. 2006 Apr; 46(2):414-20. PMID: 16213157.
      View in: PubMed
    13. Shor B, Calaycay J, Rushbrook J, McLeod M. Cpc2/RACK1 is a ribosome-associated protein that promotes efficient translation in Schizosaccharomyces pombe. J Biol Chem. 2003 Dec 05; 278(49):49119-28. PMID: 12972434.
      View in: PubMed
    14. Lobachev KS, Shor BM, Tran HT, Taylor W, Keen JD, Resnick MA, Gordenin DA. Factors affecting inverted repeat stimulation of recombination and deletion in Saccharomyces cerevisiae. Genetics. 1998 Apr; 148(4):1507-24. PMID: 9560370; PMCID: PMC1460095.
      View in: PubMed, PubMed Central
    Shor's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (121) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _